Disc Medicine's 2025 net loss smaller than estimates

Disc Medicine

26/02/2026 13:37

Overview

Biopharmaceutical company reported net loss for 2025 smaller than analyst expectations

Basic loss per share for 2025 narrower than analyst estimates

Company ended Q4 with $791 mln in cash, ensuring runway into 2029

Outlook

Disc Medicine expects topline data from Phase 3 APOLLO trial in Q4 2026

Company anticipates FDA decision on bitopertin by mid-2027

Disc Medicine expects initial data from DISC-3405 studies in 2H 2026

Result Drivers

BITOPERTIN STUDY - Co progressing with Phase 3 APOLLO study for bitopertin in EPP, with topline data expected in Q4 2026 despite FDA's Complete Response Letter

DISC-0974 RESULTS - Initial data from Phase 2 study of DISC-0974 in MF anemia showed positive anemia responses across patient subgroups

EXPANDED STUDIES - Co advancing Phase 2 study of DISC-3405 in PV and initiated Phase 1b study in SCD, with data expected in 2H 2026

Company press release: ID:nGNX7T3XnS

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
Beat
-$212.18 mln
-$216.79 mln (11 Analysts)
FY Basic EPS
Beat
-$6.01
-$6.14 (12 Analysts)
FY Operating Income
Slight Beat*
-$236.02 mln
-$238.38 mln (12 Analysts)
FY Operating Expenses
$236.02 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Disc Medicine Inc is $100.00, about 49.5% above its February 25 closing price of $66.89

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)